SCHEMBL3454155

SCHEMBL3454155

COC(=O)Cc1cc(N)n[nH]1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.41
GAA P10253 2/20 0.41
GFER P55789 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
MAPT P10636 2/20 0.41
HSP90AB1 P08238 1/20 0.41
HCAR2 Q8TDS4 3/20 0.40
KDR P35968 2/20 0.40
HSD17B10 Q99714 2/20 0.40
HTT P42858 1/20 0.40
TSHR P16473 1/20 0.39
DYRK1A Q13627 1/20 0.39
LMNA P02545 1/20 0.36
ACACA Q13085 1/20 0.36
MITF O75030 1/20 0.36
TP53 P04637 1/20 0.36
KMT2A Q03164 1/20 0.36
KDM4E B2RXH2 1/20 0.35
KDM4A O75164 1/20 0.35
KDM4B O94953 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15728525 0.83 HCAR2 (0.42) ALDH1A1SMN1; SMN2MAPTHCAR2KDR
SCHEMBL9553014 0.81 SMN1; SMN2 (0.42) ALDH1A1GAAGFERSMN1; SMN2MAPT
SCHEMBL29184279 0.81 HSP90AB1 (0.46) ALDH1A1GAAGFERSMN1; SMN2MAPT
SCHEMBL1346490 0.78 HCAR2 (0.44) ALDH1A1MAPTHCAR2KDRHSD17B10
SCHEMBL20339523 0.77 SMN1; SMN2 (0.39) ALDH1A1GAAGFERSMN1; SMN2MAPT
SCHEMBL18926448 0.76 GAA (0.58) GAASMN1; SMN2MAPTTSHRLMNA
SCHEMBL19732648 0.74
SCHEMBL1735763 0.72 ALDH1A1 (0.41) ALDH1A1GAAGFERSMN1; SMN2MAPT
SCHEMBL2173940 0.71
SCHEMBL3587984 0.70 KDM4E (0.48) ALDH1A1GAASMN1; SMN2MAPTHSP90AB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8735584-B2 Protein kinase inhibitors and use thereof MERCK PATENT GMBH (DE) 2014-05-27 US disclosed
EP-2254889-B1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2012-12-19 EP disclosed
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2011-03-03 US disclosed
EP-2254889-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF Merck Patent GmbH (DE) 2010-12-01 EP disclosed
WO-2009108670-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK SERONO S.A. (CH) 2009-09-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MAP4K2, MAP3K20, MAP4K1 ALDH1A1 4501/4885GAA 1542/4885GFER 4457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.